Skip to main content

Table 4 Selected TCR-based clinical trials for solid tumors

From: T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors

Sponsors/institutions Indication Treatment/target Countries (# of sites) NCT trial number
Adaptimmune Solid tumors MAGE-A4c1032T-cells USA/Canada (9) NCT03132922
Adaptimmune Solid tumors ADP-A2M4CD8 cells USA/Belgium/Canada/Spain (16) NCT04044859
Adaptimmune Synovial sarcoma/myxoid liposarcoma ADP-A2M4 cells USA/France/Spain/UK (25) NCT04044768
Adaptimmune HCC AFPc332T-cells USA/France/Spain/UK (20) NCT03132792
Adaptimmune Solid tumors MAGE A10c796T-cells USA/Canada/Spain (11) NCT02989064
Adaptimmune Ovarian cancer NYESO-1c259T-cells USA (5) NCT01567891
Adaptimmune Melanoma NY-ESO-1c259T-cells USA (2) NCT01350401
Adaptimmune NSCLC MAGE A10c796T-cells USA/Canada/Spain/UK (19) NCT02592577
Adaptimmune Urothelial cancer, melanoma, head and neck cancer, urothelial carcinoma MAGE A10c796T-cells USA/Canada/Spain (11) NCT02989064
Bellicum Pharmaceuticals AML, myelodysplastic syndrome, uveal melanoma BPX-701 (PRAME-TCR) infusion USA (3) NCT02743611
FHCRC NSCLC, mesothelioma WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn Lymphocytes USA (1) NCT02408016
FHCRC Merkel cell cancer FH-MCVA2TCR T-cells (MCPyV-Specific TCRs) USA (1) NCT03747484
GlaxoSmithKline Neoplasms Anti-NY-ESO-1/LAGE-1a infusion USA (25) NCT03709706
GlaxoSmithKline Synovial sarcoma NY-ESO-1c259 transduced T-cell infusion USA (8) NCT01343043
GlaxoSmithKline Solid tumors GSK3377794 (NY-ESO-1 specific TCR engineered) infusion USA/Canada/Spain/UK (15) NCT03967223
Sponsors/institutions Disease Treatment/target Countries (# of sites) NCT trial number
GlaxoSmithKline NSCLC NY-ESO-1c259T-cells USA (3) NCT02588612
GlaxoSmithKline Myxoid/round cell liposarcoma NY-ESO-1c259T-cells USA (6) NCT02992743
Immatics Solid tumors MAGEA4/8T-cells (IMA201) USA (3) NCT03247309
Immatics Solid tumors MAGE-A1 T-cells (IMA202) USA/Germany (6) NCT03441100
Immatics Solid tumors PRAME T-cells (IMA203) USA/Germany (6) NCT03686124
Kite/Gilead Sciences Solid tumors KITE-718 (genetically modified MAGE-A3/A6 TCR transduced autologous T-cells) Infusion USA (12) NCT03139370
Kite/Gilead Sciences HPV16 + cancers E7 T-cell infusion (KITE-439) USA (8) NCT03912831
NCI/NIH CC GI cancers Anti-KRAS G12D mTCR PBL infusion USA (1) NCT03745326
NCI/NIH CC GI cancers Anti-KRAS G12V mTCR PBL infusion USA (1) NCT03190941
NCI/NIH CC Breast, cervical, renal, melanoma, bladder cancer Anti-MAGE-A3 infusion USA (1) NCT02153905
NCI/NIH CC Cervical, renal, urothelial, melanoma, breast cancer Anti-MAGE-A3-DP4 infusion USA (1) NCT02111850
NCI/NIH CC Melanoma Anti-MART-1 F5 infusion USA (1) NCT00706992
NCI/NIH CC Melanoma or other cancers overexpressing p53 Anti-p53 infusion USA (1) NCT00393029
NCI/NIH CC HPV + Cancers|Vulvar Neoplasms HPV-16 E7 (E7 TCR) infusion USA (1) NCT02858310
NCI/NIH CC HPV16 + Oropharyngeal Neoplasms E7 TCR T-cells USA (1) NCT04015336; NCT04044950
NCI/NIH CC HPV-Associated Cancers Anti HPV E6 cells USA (1) NCT02280811
NCI/NIH CC Melanoma Anti-gp100:154–162 TCR TIL or PBL USA (1) NCT00509496
NCI/NIH CC Metastatic Cancers PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) PBL USA (1) NCT01273181
NCI/NIH CC Melanoma Anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL USA (1) NCT00923195
PACT Pharma, Inc Solid Tumors NeoTCR-P1 T-cells USA (6) NCT03970382
Shenzhen Second People's Hospital Multiple Myeloma|Metastatic Solid Cancers Anti-NY-ESO-1 infusion USA (1) NCT02457650
Sun Yat-sen University NPC (HLA-A2; HLA-A11, HLA-A24) EBV LMP2 antigen-specific TCR T-cell infusion China (1) NCT03925896
Sun Yat-sen University Sarcoma TAEST16001 (NY-ESO-1-specific TCR) cells China (1) NCT03462316
Xinqiao Hospital of Chongqing Solid Tumors HPV E6-specific TCR-T-cells China (1) NCT03578406
Zhujiang Hospital Solid Tumors TAEST16001 (NY-ESO-1-specific TCR) infusion China (1) NCT03159585
Guangzhou Institute of Respiratory Disease NSCLC NY-ESO-1-specific TCR-T-cells China (1) NCT03029273
Roswell Park Cancer Institute Solid Tumors NY-ESO-1 CD4-TCR CD34 + HSC on day 0; NY-ESO-1-specific CD8-positive T lymphocytes IV between days 7 and 21 USA (1) NCT03691376
Albert Einstein College of Medicine Solid Tumors Anti-ESO (cancer/test antigen) mTCR-transduced cells USA (1) NCT02774291
TCR2 Therapeutics Solid Tumors TC-210 T-cells USA (5) NCT03907852
  1. FHCRC Fred Hutchinson Cancer Research Center, NCI/NIH CC National Cancer Institute/National Institutes of Health Clinical Center, AML acute myeloid leukemia, GI gastrointestinal, HCC hepatocellular carcinoma, NPC nasopharyngeal carcinoma, NSCLC non-small cell lung cancer